The Toll Booth That Claimed the Highway
The fraud 1.9 lakh investors didn't see coming.
A toll booth earns ₹50 per car; fair.
Now, imagine it starts reporting the value of every car as revenue. A ₹1 crore car crosses, and the booth reports: “earned ₹1 crore”.
Sounds ridiculous. But according to SEBI’s 109-page interim order, that’s exactly what Rajesh Exports allegedly did.
They bought Valcambi, the world’s largest gold refiner. Real business: a tiny refining fee. But instead of reporting that fee, they allegedly booked the entire gold value passing through as revenue. Result?
Valcambi’s audited revenue: ~₹500 crore per year.
Rajesh Exports’ reported revenue: ₹2-4 lakh crore. A 400x difference!
Note: During FY 2024-25 REL’s shareholding in ACC Energy Storage Pvt. Ltd. was reduced from 100% to 51.05%.
Look at those layers. India → Singapore shell → Swiss holding → Valcambi. Three levels of accounting for one real business with 0.02% PAT margin.
A company that fails any of these four checks does not belong in a long-term portfolio:
Complex structure: No public subsidiary accounts. Walk away.
Receivables growing faster than revenue: Sales may not be real.
Low PAT-to-cash flow: Accounting profit isn’t converting into cash.
Audit fees not keeping pace: Oversight has likely been captured.
Rajesh Exports failed every single one. That is the point. Not to name-and-shame, but to internalise the pattern.
A company that cannot pass these basic checks is a structural risk no valuation framework can fix. Capital safety is the only rational foundation for long-term compounding.
Finology’s Exclusive Updates
01. From Finology 30
Dashboard Update: 2 Core Stock research reports were refreshed, and 2 new notifications were added on June 2.
Stock Update: Finology 30’s latest stock goes live tomorrow.
It’s a business that looks ordinary through the rear-view mirror and very different through the windshield.
The full research report, along with the company name and Buy It Below price, is available in the Finology 30 dashboard.
02. From Ticker: The GLP-1 Delivery Boom
Demand for GLP-1 weight-loss drugs and insulin pens is driving strong growth for Indian precision engineering and CDMO companies that manufacture delivery devices for global pharma players.
How to Spot the “Device Winners” on Ticker:
Segment Revenue Shift: Look for rising revenue contribution from Medical Devices or Device Components.
CWIP Transformation: Track CWIP moving into Net Fixed Assets, indicating new capacity going live.
DuPont Analysis: Look for ROE growth driven by stronger margins and asset efficiency.
Use Ticker to identify companies benefiting from the growing global demand for drug delivery devices.
Game Time!
What’s your dilemma?
A company faces governance allegations.
You estimate:
70% chance allegations are false → stock doubles.
30% chance allegations are true → stock falls 80%.
That’s all in The Finology Letter
Hope today’s edition felt useful and worth your time.
If it did, drop a like and comment how. Also, if you’d like us to cover more (or less) of such content, do tell. We love to get better for our people.